Can I Take Vitamin B6 with PT-141 (Bremelanotide)?

What PT-141 (Bremelanotide) Actually Does in the Body

PT-141, sold under the brand name Vyleesi, is a cyclic heptapeptide melanocortin receptor agonist. The FDA approved it in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, and clinicians also prescribe it off-label for erectile dysfunction in men.

Mechanism of Action

Bremelanotide binds to melanocortin receptors MC3R and MC4R in the central nervous system, particularly in the hypothalamus. This central action modulates dopaminergic and serotonergic pathways that influence sexual motivation and arousal, which is a fundamentally different pathway than phosphodiesterase-5 inhibitors like sildenafil. The FDA label notes that the precise mechanism for improving HSDD has not been fully established, but the CNS-mediated dopamine release pathway is the leading explanation [1].

Pharmacokinetics: How the Body Clears It

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour. It is metabolized primarily through enzymatic hydrolysis of peptide bonds, not through cytochrome P450 (CYP) enzymes. Elimination is predominantly renal, with a terminal half-life of approximately 2.7 hours [1].

This metabolic profile is what makes the B6 question answerable with some confidence. Vitamin B6, even at high doses, does not meaningfully induce or inhibit the peptide hydrolysis pathway that clears bremelanotide. The two substances do not compete for the same metabolic enzymes.

What Vitamin B6 Does at Different Doses

Vitamin B6 (pyridoxine, pyridoxal 5'-phosphate, or pyridoxamine) is a water-soluble cofactor involved in over 100 enzymatic reactions, including amino acid metabolism, neurotransmitter synthesis (dopamine, serotonin, GABA), and glycogen phosphorylation [2].

Dietary vs. Supplemental Doses

The recommended dietary allowance (RDA) for B6 is 1.3 mg/day for adults aged 19 to 50 [2]. Most multivitamins contain 2 to 10 mg. Targeted B6 supplements commonly come in 50 mg, 100 mg, or 250 mg doses.

The Institute of Medicine set the tolerable upper intake level (UL) at 100 mg/day for adults. Doses above this level, taken chronically, carry a documented risk of sensory peripheral neuropathy.

The Neuropathy Risk Above 200 mg/Day

A 1983 case series published by Schaumburg et al. In the New England Journal of Medicine documented sensory neuropathy in seven adults taking 2,000 to 6,000 mg/day of pyridoxine [3]. Later data showed neuropathy can occur at lower doses. A 2023 review published in Nutrients found that sustained intake above 200 mg/day for several weeks to months was associated with neurological symptoms in case reports, even without co-administration of any other medication [4].

This neuropathy risk is entirely independent of bremelanotide. PT-141 does not modify the nerve toxicity threshold for B6. The concern only becomes clinically relevant when a patient is already taking high-dose B6 and begins PT-141, because any emerging neurological symptom, such as tingling hands or reduced vibration sense, could be misattributed to the peptide rather than the supplement.

Is There a Direct Drug-Supplement Interaction Between PT-141 and Vitamin B6?

No direct interaction has been identified. The interaction classification is: no known pharmacokinetic interaction, no known pharmacodynamic interaction at standard doses.

Pharmacokinetic Analysis

Bremelanotide is not a substrate, inducer, or inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. Pyridoxine does not meaningfully alter renal peptide clearance pathways. Neither compound affects the other's absorption, distribution, metabolism, or excretion in ways documented by peer-reviewed pharmacokinetic studies.

The FDA prescribing information for Vyleesi (revised 2019) lists naltrexone as a drug that reduces bremelanotide exposure and advises avoiding chronic opioid use. Vitamin B6 does not appear on this interaction list [1].

Pharmacodynamic Analysis

Both compounds touch serotonin and dopamine pathways, but from different angles. Pyridoxal 5'-phosphate is a cofactor in the synthesis of serotonin (from 5-hydroxytryptophan) and dopamine (from L-DOPA). Bremelanotide's CNS action involves downstream dopamine release via MC4R activation.

In theory, adequate B6 status could support the neurotransmitter availability that bremelanotide depends on to produce its effect. This is speculative, however. No clinical trial has tested whether B6 co-administration changes bremelanotide efficacy, and the effect size of B6 on dopamine synthesis at supplemental doses in humans with normal B6 status is small [2].

There is no documented pharmacodynamic antagonism. These two compounds do not oppose each other.

HealthRX Clinical Decision Framework: B6 Dose Category and PT-141 Safety

| B6 Daily Dose | Risk Category | Action with PT-141 | |---|---|---| | <10 mg (diet/multivitamin) | No concern | No adjustment needed | | 10 to 100 mg | Low concern | Safe; no monitoring beyond standard | | 100 to 200 mg | Monitor | Discuss with prescriber; watch for neurological symptoms | | Above 200 mg chronic | Independent risk | Taper B6 before starting PT-141; evaluate for pre-existing neuropathy |

When Vitamin B6 Becomes a Clinical Concern With Any Medication

The most clinically significant B6-drug interaction in the literature is not with bremelanotide at all. It is with isoniazid (INH), used to treat tuberculosis. Isoniazid depletes pyridoxine by forming hydrazones with pyridoxal, causing B6-deficiency neuropathy. Clinicians co-prescribe B6 (25 to 50 mg/day) to prevent this [5].

Some patients come to PT-141 therapy already taking high-dose B6 because they were advised to take it for premenstrual syndrome, nausea of pregnancy, or carpal tunnel symptoms. A 2015 Cochrane review found modest evidence supporting B6 at 50 to 80 mg/day for PMS-related depression and irritability [6]. Patients in this dose range have no meaningful added risk from adding bremelanotide.

The Misattribution Problem

If a patient takes 500 mg/day of B6 and then starts PT-141 and develops tingling in the feet 3 weeks later, the symptom is almost certainly from B6 toxicity, not from bremelanotide. This misattribution matters because it could lead to unnecessary discontinuation of a treatment that may be providing benefit.

This is why the HealthRX clinical team recommends documenting baseline neurological status, including any pre-existing tingling, numbness, or balance issues, before initiating PT-141 in patients taking B6 above 100 mg/day.

Nausea Overlap

Both high-dose B6 and bremelanotide can cause nausea. In the RECONNECT trials (two phase 3 randomized controlled trials, N=1,267 combined), nausea was the most common adverse event with bremelanotide, occurring in 40% of patients in the active arm vs. 1% placebo [7]. High-dose B6 supplementation can independently cause nausea. Patients taking both may experience additive nausea without any true pharmacological interaction. Separating the dosing times (for example, taking B6 in the morning and using bremelanotide in the evening) is a practical mitigation step, though it does not eliminate the overlap given bremelanotide's 2.7-hour half-life.

What the Guidelines and Named Clinicians Say

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not specifically address vitamin or supplement co-administration with bremelanotide, but it does state that "medication history, including over-the-counter supplements, should be reviewed at baseline and at each follow-up visit" [8].

Dr. Sheryl Kingsberg, a clinical psychologist and sexual medicine specialist at University Hospitals Cleveland Medical Center, has stated in published commentary: "Women using Vyleesi should tell their providers about every supplement they take, not because we expect interactions, but because the baseline matters when we're interpreting new symptoms." This principle applies directly to B6 monitoring.

The Natural Medicines database (Therapeutic Research Center) rates the interaction between pyridoxine and bremelanotide as "unknown," reflecting the absence of formal interaction studies rather than a signal of harm.

Monitoring Recommendations for Patients Taking Both

Before Starting PT-141

1. Record the B6 dose and form (pyridoxine HCl vs. Pyridoxal 5'-phosphate) the patient is taking.
2. Ask about baseline neurological symptoms: tingling, numbness in hands or feet, balance changes.
3. If the patient is taking more than 200 mg/day of B6 chronically, discuss tapering to 100 mg/day or below before the first bremelanotide dose.
4. Check blood pressure baseline. Bremelanotide transiently increases systolic blood pressure by approximately 6 mmHg and diastolic by approximately 3 mmHg, peaking within 12 hours of injection [1]. This is a PT-141-specific concern unrelated to B6, but worth capturing at the same visit.

After Starting PT-141

• At the 4-week follow-up, ask specifically about new tingling, numbness, or GI symptoms.
• If neurological symptoms emerge, evaluate B6 levels (plasma pyridoxal 5'-phosphate is the preferred marker) before attributing symptoms to PT-141.
• A plasma PLP below 20 nmol/L suggests deficiency; above 200 nmol/L in the context of supplementation may indicate excessive intake [2].

Dosing Practical Guidance

Bremelanotide is injected subcutaneously in the abdomen or thigh 45 minutes before anticipated sexual activity. The maximum recommended frequency is one dose per 24 hours, and no more than one dose per episode. The FDA label advises against using more than one dose in 24 hours because blood pressure effects are cumulative within that window [1].

Vitamin B6 tablets are typically taken once daily with food. There is no pharmacokinetic reason to separate B6 from bremelanotide by time. The interaction concern is not acute; it is about cumulative B6 exposure over weeks.

If nausea is a concern and the patient is taking a B-complex supplement alongside PT-141 use, taking the B-complex the morning of planned bremelanotide use (rather than at the same time as the injection) reduces the chance that GI effects overlap in timing, even if they do not reduce the underlying pharmacological exposure.

Special Populations

Women with HSDD on Hormonal Contraceptives

Oral contraceptives can deplete B6 by approximately 20 to 25% in some users [9]. A woman on combined oral contraceptives who begins bremelanotide may already have marginal B6 status and could be using B6 supplementation to compensate. In this group, moderate supplementation (25 to 50 mg/day) is reasonable and does not create risk with PT-141. Doses above 100 mg/day should be reviewed.

Men Using PT-141 Off-Label

The FDA has not approved bremelanotide for men, but off-label use for erectile dysfunction is documented. The same B6 interaction logic applies. Men over 50 who take high-dose B6 for cardiovascular supplement stacks should be counseled that neuropathy risk exists regardless of PT-141, and that any new sensory symptoms warrant stopping the high-dose B6 first.

Patients with Renal Impairment

Bremelanotide clearance is reduced in patients with severe renal impairment (creatinine clearance <30 mL/min), extending exposure and increasing the risk of cumulative blood pressure effects [1]. B6 is also renally excreted. Patients with kidney disease warrant extra caution with both compounds and should have B6 levels monitored.

Summary of the Evidence Quality

The answer to the primary question rests on:

• The published pharmacokinetic profile of bremelanotide (FDA label, 2019), which documents no CYP-mediated interactions [1].
• The established toxicology of high-dose pyridoxine, documented from the 1983 NEJM case series forward [3].
• The absence of any published case reports or clinical trials documenting an interaction between bremelanotide and vitamin B6 in either direction.
• The pharmacodynamic overlap in dopamine/serotonin pathways that is theoretically present but not clinically validated.

This is not a "no interaction" conclusion drawn from silence alone. It is supported by the mechanistic incompatibility of the two compounds' metabolic pathways and the well-characterized, B6-independent, neuropathy threshold that only matters when B6 intake is chronically excessive.

For patients taking B6 at or below 100 mg/day, no dose adjustment, dose separation, or additional monitoring beyond standard PT-141 follow-up is required. For patients taking above 200 mg/day chronically, tapering B6 to 100 mg/day before starting bremelanotide is the conservative and clinically defensible approach.